Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV’s Immunological Achilles’ Heel DOI Creative Commons

Anastasia Lankina,

Marta Brezmes Raposo, Alexander Hargreaves

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(5), P. 435 - 435

Published: April 22, 2025

Human cytomegalovirus (HCMV) is a critical pathogen in immunocompromised populations, such as organ transplant recipients well congenitally infected neonates with immature immune systems. Despite decades of research and the growing financial burden associated management HCMV, there no licensed vaccine to date. In this review, we aim outline complexity HCMV antigens it presents journey challenges developing an effective vaccine, further highlight recent analyses most successful candidate so far—gB/MF59.

Language: Английский

Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV’s Immunological Achilles’ Heel DOI Creative Commons

Anastasia Lankina,

Marta Brezmes Raposo, Alexander Hargreaves

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(5), P. 435 - 435

Published: April 22, 2025

Human cytomegalovirus (HCMV) is a critical pathogen in immunocompromised populations, such as organ transplant recipients well congenitally infected neonates with immature immune systems. Despite decades of research and the growing financial burden associated management HCMV, there no licensed vaccine to date. In this review, we aim outline complexity HCMV antigens it presents journey challenges developing an effective vaccine, further highlight recent analyses most successful candidate so far—gB/MF59.

Language: Английский

Citations

0